Pharmaceutical major Novartis Investors are increasingly optimistic about some of the company’s biggest growth drugs, even as they question whether the company can maintain growth beyond 2031 and offset the financial impact of patent expirations on older drugs.
The Swiss drugmaker now expects peak sales of $18 billion for its multiple sclerosis drug Kesimpta, leukemia drug Cemblix and cholesterol drug Lekvio, exceeding previous estimates of $14 billion.
CEO Vasu Narasimhan said the upgrade was driven primarily by strong commercial performance, pointing to the growing market share of Kesimpta and Cembrix in the US and Asia, as well as strong demand for Lekvio.
Vasu Narasimhan, CEO of Novartis AG, makes a presentation in the Roosevelt Room of the White House on Friday, December 19, 2025 in Washington, DC, USA.
Will Oliver | Bloomberg | Getty Images
“What’s driving these upgrades is really the commercial performance in the market,” Narasimhan told reporters Thursday.
Shares fell 2.4% in mid-morning trading in Switzerland. The question for investors will be whether these drugs can grow fast enough to offset the loss in sales as other drugs face competition from cheaper rivals entering the market.
Novartis stock price since the beginning of the year.
Still, despite stronger expectations for some key growth drugs, the overall growth outlook looked slightly cautious.
Novartis forecasts annual sales growth of 5% through 2031, slightly less ambitious than its previous guidance of 5% to 6% through 2030, but over a five-year period.
Chief Executive Basu Narasimhan said the revised outlook reflects the company’s expected entry into generic competition for its breast cancer drug Kisqari in the United States in the second half of 2031.
Citi analysts noted that the 2031 revenue outlook is about 3% above consensus, adding that they expect the market to remain skeptical about growth beyond 2031 until more pipeline data is available.
Novartis has faced several clinical setbacks recently. The high-profile cardiovascular peracalcen trial in September showed no improvement in cardiovascular outcomes. The next day, the company’s drug deldesiran, which treats muscle-wasting disorders, failed in a late-stage trial, sending the stock down nearly 11%, its worst single-day decline since 1987.
Narasimhan defended the drug company’s capital allocation strategy after the failure of its investigational drug derdesirane, which it acquired in a $12 billion deal with Avidity Biosciences earlier this year.
Narasimhan said shareholders have differing views on the deal, with some favoring a more aggressive deal and others favoring a different approach. But he said Novartis remains confident in its strategy, noting that the company is a top performer in its sector with total shareholder returns of 275% over the past 10 years.
Tune in to Novartis CEO Vasu Narasimhan’s appearance on CNBC TV at 11 a.m. ET. Watch in real time on CNBC+ or CNBC Pro streams.
